{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:47:48Z","timestamp":1794646068550,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early cancer detection improves survival; however, most cancer types do not have guideline-recommended screening. We previously reported the first PATHFINDER study that established feasibility of cancer screening with a blood-based multi-cancer early detection (MCED) test that predicts cancer signal origin (CSO) to guide diagnostic workup. The prospective, interventional PATHFINDER 2 study expands clinical evidence for the MCED test by evaluating co-primary endpoints of MCED performance metrics and safety in participants aged 50\u2009years or older without clinical suspicion of cancer. Performance measures included cancer detection rate, positive and negative predictive values, episode sensitivity, specificity and CSO prediction accuracy. Safety was evaluated in terms of number and type of invasive procedures performed and adverse events due to diagnostic testing, after 12\u2009months of follow-up. Endpoints were analyzed descriptively; no hypothesis testing was performed. Between December 2021 and July 2024, 35,878 participants were enrolled. Among 32,007 performance-analyzable participants, cancer detection rate was 0.54% (95% confidence interval (CI): 0.47\u22120.63%), positive predictive value was 60.3% (95% CI: 54.5\u221265.8%), negative predictive value was 99.2% (95% CI: 99.1\u221299.3%) and specificity was 99.64% (95% CI: 99.57\u221299.70%). Episode sensitivity was 39.3% (95% CI: 34.9\u221244.0%; all cancers) and 69.8% (95% CI: 62.8\u221276.0%; prespecified 12-cancer subgroup). Positive and negative likelihood ratios were 108.9 (95% CI: 87.6\u2212135.2) and 0.61 (95% CI: 0.56\u22120.66), respectively, and the number needed to screen to detect one cancer was 185 (95% CI: 159\u2212215). CSO prediction accuracy was 91.3%. Among 35,335 safety-analyzable participants, 213 (0.6%) had invasive procedure(s) after a positive MCED test; 90.5% were nonsurgical. No serious study-related adverse events were reported by the time of this analysis. These results provide insights into performance and safety of the MCED test in an intended-use population. Randomized trials and longer follow-up are needed to assess the clinical utility of MCED tests. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05155605\" ext-link-type=\"uri\">NCT05155605<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04618-w","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:01:49Z","timestamp":1790110909000},"page":"3760-3769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-8262","authenticated-orcid":false,"given":"Nima","family":"Nabavizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dax","family":"Kurbegov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-8674","authenticated-orcid":false,"given":"Raymond H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Stipec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-7894","authenticated-orcid":false,"given":"Kevin C.","family":"Oeffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Demeure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James W.","family":"Lillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kaltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1931-9268","authenticated-orcid":false,"given":"Alan","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Tahhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Poklepovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Lopatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McCusker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik V.","family":"Giridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"4618_CR1","first-page":"e70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H. & Jemal, A. Cancer statistics, 2026. CA Cancer J. Clin. 76, e70043 (2026).","journal-title":"CA Cancer J. Clin."},{"key":"4618_CR2","unstructured":"NORC at the University of Chicago. Percent of cancers detected by screening: all cancer, all ages. https:\/\/cancerdetection.norc.org\/ (2022)."},{"key":"4618_CR3","doi-asserted-by":"publisher","first-page":"187585922413087","DOI":"10.1177\/18758592241308754","volume":"42","author":"JJ Ofman","year":"2025","unstructured":"Ofman, J. J. et al. Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States. Cancer Biomark. 42, 18758592241308754 (2025).","journal-title":"Cancer Biomark."},{"key":"4618_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745\u2013759 (2020).","journal-title":"Ann. Oncol."},{"key":"4618_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","volume":"32","author":"EA Klein","year":"2021","unstructured":"Klein, E. A. et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 32, 1167\u20131177 (2021).","journal-title":"Ann. Oncol."},{"key":"4618_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi, A. et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40, 1537\u20131549 (2022).","journal-title":"Cancer Cell"},{"key":"4618_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402, 1251\u20131260 (2023).","journal-title":"Lancet"},{"key":"4618_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/2767-9764.CRC-25-0723","volume":"6","author":"EK O\u2019Donnell","year":"2026","unstructured":"O\u2019Donnell, E. K. et al. Diagnostic outcomes among patients with positive multi-cancer early detection test results. Cancer Res. Commun. 6, 511\u2013515 (2026).","journal-title":"Cancer Res. Commun."},{"key":"4618_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/21501319251329290","volume":"16","author":"RT Hurt","year":"2025","unstructured":"Hurt, R. T. et al. Implementation of a multicancer detection (MCD) test in a tertiary referral center in asymptomatic patients: an 18-month prospective cohort study. J. Prim. Care Community Health 16, 21501319251329290 (2025).","journal-title":"J. Prim. Care Community Health"},{"key":"4618_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64094-7","volume":"16","author":"M Matrana","year":"2025","unstructured":"Matrana, M. et al. Real-world data and clinical experience from over 100,000 multi-cancer early detection tests. Nat. Commun. 16, 9625 (2025).","journal-title":"Nat. Commun."},{"key":"4618_CR11","unstructured":"Agarwal, G., Carlson, J. W. & Broyles, D. R. Implementation of a multi-cancer early detection test using a centralized model within a multi-state health system. https:\/\/grail.com\/wp-content\/uploads\/2023\/06\/Agarwal_ASCO-2023_Patient-Navigation-Mercy_Poster_FINAL.pdf (2023)."},{"key":"4618_CR12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222499","volume":"307","author":"CI Lee","year":"2023","unstructured":"Lee, C. I. et al. National performance benchmarks for screening digital breast tomosynthesis: update from the Breast Cancer Surveillance Consortium. Radiology 307, e222499 (2023).","journal-title":"Radiology"},{"key":"4618_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2310336","volume":"390","author":"TF Imperiale","year":"2024","unstructured":"Imperiale, T. F. et al. next-generation multitarget stool DNA test for colorectal cancer screening. N. Engl. J. Med. 390, 984\u2013993 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4618_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung, D. C. et al. A cell-free DNA blood-based test for colorectal cancer screening. N. Engl. J. Med. 390, 973\u2013983 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4618_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gie.2016.09.025","volume":"85","author":"DJ Robertson","year":"2017","unstructured":"Robertson, D. J. et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointest. Endosc. 85, 2\u201321 (2017).","journal-title":"Gastrointest. Endosc."},{"key":"4618_CR16","doi-asserted-by":"publisher","first-page":"971\u2212987","DOI":"10.1001\/jama.2021.0377","volume":"325","author":"DE Jonas","year":"2021","unstructured":"Jonas, D. E. et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 325, 971\u2212987 (2021).","journal-title":"JAMA"},{"key":"4618_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1569-9056(02)00053-2","volume":"1","author":"MB Gretzer","year":"2002","unstructured":"Gretzer, M. B. & Partin, A. W. PSA levels and the probability of prostate cancer on biopsy. Eur. Urol. Open Sci. 1, 21\u201327 (2002).","journal-title":"Eur. Urol. Open Sci."},{"key":"4618_CR18","unstructured":"Chang, E. T. et al. Leveling the playing field when comparing multi-cancer early detection (MCED) tests: weighting by cancer type and stage. https:\/\/grail.com\/wp-content\/uploads\/2023\/10\/Chang_EDCC-2023_Cancer-Standardization_Poster_FINAL.pdf (2023)."},{"key":"4618_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2018.10400","volume":"320","author":"J Melnikow","year":"2018","unstructured":"Melnikow, J. et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 320, 687\u2013705 (2018).","journal-title":"JAMA"},{"key":"4618_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jama.2017.19872","volume":"320","author":"JJ Kim","year":"2018","unstructured":"Kim, J. J., Burger, E. A., Regan, C. & Sy, S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA 320, 706\u2013714 (2018).","journal-title":"JAMA"},{"key":"4618_CR21","doi-asserted-by":"crossref","unstructured":"Lin, J. S., Perdue, L. A., Henrikson, N. B., Bean, S. I. & Blasi, P. R. Screening for Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality, 2021).","DOI":"10.1001\/jama.2021.4417"},{"key":"4618_CR22","doi-asserted-by":"crossref","unstructured":"Massart, M., Raoof, S., Hubbell, E. & Klein, E. Molecular cancer signal localization in multi-cancer early detection (MCED) testing minimizes radiation and imaging burden compared to whole-body imaging approaches. Cancer Prev. Res. (Phila.) 19, 353\u2212360 (2026).","DOI":"10.1158\/1940-6207.CAPR-25-0283"},{"key":"4618_CR23","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/2767-9764.CRC-24-0351","volume":"5","author":"EA Klein","year":"2025","unstructured":"Klein, E. A., Church, T. R., Clarke, C. A. & Hubbell, E. Modeled benefit of individual cancer signal origin prediction for multi-cancer early detection. Cancer Res. Commun. 5, 814\u2013824 (2025).","journal-title":"Cancer Res. Commun."},{"key":"4618_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaf011","volume":"9","author":"C Tyson","year":"2025","unstructured":"Tyson, C. et al. Tumor localization strategies of multicancer early detection tests: a quantitative assessment. JNCI Cancer Spectr. 9, pkaf011 (2025).","journal-title":"JNCI Cancer Spectr."},{"key":"4618_CR25","first-page":"659","volume":"29","author":"M Gitlin","year":"2023","unstructured":"Gitlin, M., McGarvey, N., Shivaprakash, N. & Cong, Z. Time duration and health care resource use during cancer diagnoses in the United States: a large claims database analysis. J. Manag. Care Spec. Pharm. 29, 659\u2013670 (2023).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"4618_CR26","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jama.2023.25844","volume":"331","author":"JT Henderson","year":"2024","unstructured":"Henderson, J. T., Webber, E. M., Weyrich, M. S., Miller, M. & Melnikow, J. Screening for breast cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 331, 1931\u20131946 (2024).","journal-title":"JAMA"},{"key":"4618_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1148\/radiol.2021203936","volume":"300","author":"S Hofvind","year":"2021","unstructured":"Hofvind, S. et al. Interval and subsequent round breast cancer in a randomized controlled trial comparing digital breast tomosynthesis and digital mammography screening. Radiology 300, 66\u201376 (2021).","journal-title":"Radiology"},{"key":"4618_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton, J. J. et al. Prostate-specific antigen\u2013based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 319, 1914\u20131931 (2018).","journal-title":"JAMA"},{"key":"4618_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09261-5","volume":"22","author":"A Kim","year":"2022","unstructured":"Kim, A., Chung, K. C., Keir, C. & Patrick, D. L. Patient-reported outcomes associated with cancer screening: a systematic review. BMC Cancer 22, 223 (2022).","journal-title":"BMC Cancer"},{"key":"4618_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1470-2045(24)00645-4","volume":"26","author":"L Nadauld","year":"2025","unstructured":"Nadauld, L. et al. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. Lancet Oncol. 26, 165\u2013174 (2025).","journal-title":"Lancet Oncol."},{"key":"4618_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/1055-9965.EPI-23-1018","volume":"33","author":"E Hubbell","year":"2024","unstructured":"Hubbell, E., Clarke, C. A., Smedby, K. E., Adami, H.-O. & Chang, E. T. Potential for cure by stage across the cancer spectrum in the United States. Cancer Epidemiol. Biomarkers Prev. 33, 206\u2013214 (2024).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"4618_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70075","volume":"131","author":"J Chhatwal","year":"2025","unstructured":"Chhatwal, J. et al. The impact of multicancer early detection tests on cancer stage shift: a 10-year microsimulation model. Cancer 131, e70075 (2025).","journal-title":"Cancer"},{"key":"4618_CR33","doi-asserted-by":"crossref","unstructured":"Giridhar, K. V. et al. PATHFINDER 2: a prospective study to evaluate safety and performance of a multi-cancer early detection test in a population setting. https:\/\/grail.com\/wp-content\/uploads\/2024\/04\/4784_Giridhar_AACR-2024-Pathfinder2-Study-Design_Poster_Final.pdf (2024).","DOI":"10.1158\/1538-7445.AM2024-4784"},{"key":"4618_CR34","doi-asserted-by":"crossref","unstructured":"Gadgeel, S. et al. Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi\u2011cancer early detection test in a population setting. https:\/\/grail.com\/wp-content\/uploads\/2025\/09\/C145.Gadgeel.AACR-2025-Cancer-Health-Disparities.PF2-Baseline-Demographics.FINAL_.pdf (2025).","DOI":"10.1158\/1538-7755.DISP25-C145"},{"key":"4618_CR35","unstructured":"Atwood, C. et al. REFLECTION: real-world evidence study of multi-cancer early detection (MCED) among veterans in the Veterans Affairs Healthcare System (VA). https:\/\/grail.com\/wp-content\/uploads\/2025\/10\/Atwood.EDCC-2025.REFLECTION-VA.Slides_Final-1.pdf (2025)."},{"key":"4618_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/aje\/kwk075","volume":"165","author":"P Pinsky","year":"2007","unstructured":"Pinsky, P. et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Epidemiol. 165, 874\u2013881 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"4618_CR37","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3390\/cancers14194818","volume":"14","author":"RD Neal","year":"2022","unstructured":"Neal, R. D. et al. Cell-free DNA\u2013based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers 14, 4818 (2022).","journal-title":"Cancers"},{"key":"4618_CR38","unstructured":"Spielberger, C., Gorsuch, R., Lushene, R., Vagg, P. & Jacobs, G. Manual for the State-Trait Anxiety Inventory (Consulting Psychologists Press, 1983)."},{"key":"4618_CR39","doi-asserted-by":"publisher","first-page":"140\u2212149","DOI":"10.1177\/09691413241228041","volume":"31","author":"JY Dai","year":"2024","unstructured":"Dai, J. Y. et al. Clinical performance and utility: a microsimulation model to inform the design of screening trials for a multi-cancer early detection test. J. Med. Screen. 31, 140\u2212149 (2024).","journal-title":"J. Med. Screen."},{"key":"4618_CR40","unstructured":"US Preventive Services Task Force. Breast Cancer: Screening. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/breast-cancer-screening (2024)."},{"key":"4618_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"National Lung Screening Trial Research Team.","year":"2011","unstructured":"National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395\u2013409 (2011).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04618-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:31:06Z","timestamp":1792038666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4618"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04618-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.N. has served in a consulting\/advisory role for GRAIL, Inc. and Exact Sciences and has received honoraria from Roche Diagnostics and MJH Life Sciences. C.M. has served in a consulting\/advisory role for GRAIL. D.K. is an employee of HCA Healthcare and holds stock in the company. M. Matrana is an employee of Ochsner Health; has served in a consulting\/advisory role for AstraZeneca and Tempus; and has served on a speakers\u2019 bureau for Bristol Myers Squibb, AstraZeneca, Merck, Eisai, Genentech, Janssen, Exelixis, Seagen and Daiichi Sankyo\/Lilly. S.G. has served in a consulting\/advisory role for Genentech\/Roche, AstraZeneca, Bristol Myers Squibb, Takeda, Daiichi Sankyo, Lilly, Pfizer, Mirati Therapeutics, Merck, Eisai, Gilead Sciences, Arcus Biosciences, Bayer, Regeneron, AbbVie, Gilead Sciences, Astellas Pharma and Johnson & Johnson\/Janssen and received travel expenses from Mirati Therapeutics and Merck. K.C.O. has served in a consulting\/advisory and leadership role for Maia Oncology and holds stock in the company. M.J.D. holds stock in Agenus; has received honoraria from AADi, White Hawk Therapeutics, Crinetics Pharmaceuticals, Loxo\/Lilly and Corcept Therapeutics; and has served in a consulting\/advisory role for Loxo\/Lilly, Orphagen, Bayer, TD2, Theralink, OnCusp, Pfizer, Boehringer Ingelheim and Crinetics Pharmaceuticals. J.W.L. holds patents with Chinook Therapeutics (a Novartis company). R.K. has served in a consulting\/advisory role for Previvor Edge and holds stock in the company. J.T. holds stock in Novo Nordisk and Vertex. A.P. has served in a consulting\/advisory role for IO Biotech and on a speakers\u2019 bureau for Natera. D.R. has served in a consulting\/advisory role for Ipsen, Taiho Pharmaceuticals, Seattle Genetics\/Astellas, Mirati Therapeutics, GRAIL and Roche\/Genentech. M.L. is an employee of GRAIL, Inc. and holds stock in the company. C.M. is an employee of GRAIL, Inc. and holds stock in the company and was previously employed by Genentech and holds stock in the company. M. McCusker is an employee of GRAIL, Inc. and holds stock in GRAIL, Roche and Illumina. K.V.G. has served in a consulting\/advisory role for Lilly, Onviv, Novartis, Medscape, Clinical Education Alliance, Quantum Leap Healthcare Collaborative, GRAIL, Conexiant and the Association for Molecular Pathology and received travel expenses from GRAIL. R.H.K., G.S., A.R. and S.T. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}